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Myocardial Viability Imaging
Dead or Alive?*
Katherine C. Wu, MD
Baltimore, Maryland
The concept of hibernating myocardium originated from
observations in the 1970s that the myocardial dysfunction
seen in patients with chronic coronary artery disease (CAD)
was not always permanent (1). The fact that revasculariza-
tion with coronary artery bypass grafting (CABG) could
result in the recovery of contractile function in previously
akinetic segments led to the development of numerous
imaging techniques to differentiate viable from nonviable
myocardium. Although enhanced regional and global left
ventricular (LV) function can be demonstrated and often
translates into symptomatic benefit in patients with severe
ischemic LV dysfunction, the impact on survival of identi-
fying and then revascularizing viable but dysfunctional
myocardium remains unclear. Previous outcome studies
using various imaging modalities to assess viability were
small and retrospective in nature, and predated the era of
modern medical therapy (2,3). Only recently have 2 pro-
spective, randomized trials comparing medical therapy to
surgical or percutaneous revascularization based on pre-
intervention viability testing been completed and reported,
See page 825
but they raise more questions than answers (4,5). Both the
viability substudy of the multicenter STICH (Surgical
Treatment for Ischemic Heart Failure) trial and the
HEART (Heart Failure Revascularisation Trial) were neg-
ative for their primary endpoints of all-cause mortality.
Although HEART was underpowered because of underen-
rollment, the STICH substudy demonstrated lower rates of
the secondary composite endpoint of cardiovascular death or
cardiovascular hospitalization. Nonetheless, these results
question the clinically accepted dogma of routinely requir-
ing viability assessment prior to all revascularization proce-
dures in these high-risk patients.
How can we reconcile the results of Gerber et al. (6),
reported in this issue of the Journal, with those of STICH
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delayed-enhancement cardiac magnetic resonance imaging
(DE-CMR), which depends upon the premise that regions
of nonviable fibrosis and scar have increased volumes of
distribution and reduced contrast washout rates of gadolin-
ium compared with normal myocardium, and thus appear
hyperenhanced. DE-CMR viability is assessed on a re-
gional, segmental basis with 50% transmural involvement
of the wall defining a nonviable segment. Significant viabil-
ity is present if 4 dysfunctional segments have 50%
ransmural hyperenhancement. In this nonrandomized, ob-
ervational study of 144 patients with mean LV ejection
raction of 24  7%, 86 patients underwent “full revascu-
arization” via either CABG or percutaneous coronary
ntervention (PCI), 12 underwent “incomplete PCI,” and 46
ere treated medically. The primary endpoint was all-cause
ortality. The worst outcome was observed in patients with
E-CMR viability who were treated medically or with
ncomplete PCI, whereas the best survival rate was seen in
hose with completely revascularized viable myocardium.
atients with nonviable myocardium had intermediate sur-
ival rates, irrespective of their revascularization status. In
atients with viability, medical therapy was associated with
4.6-fold increased risk of death compared with those who
ere completely revascularized, whereas there was no sig-
ificant difference in survival with medical therapy versus
evascularization in patients without viability. The authors also
erformed further propensity score matching to try to mini-
ize baseline group differences, which were significant and
ncluded more severe heart failure symptoms and lesser extents
f myocardial viability in the medically treated/incompletely
evascularized patients. The data support those of prior smaller,
onrandomized studies using nuclear and dobutamine echo-
ardiography to assess viability, as summarized in a meta-
nalysis (2) but are incongruent with STICH and HEART.
hat factors account for the differences?
Although the present study is unique in that it is the only
ublished outcome study using DE-CMR in which revas-
ularization versus medical therapy was compared, and the
uthors should be commended for their perseverance and
areful work, there are limitations with the study design.
election bias is extremely difficult to overcome in a non-
andomized study, propensity matching analysis notwith-
tanding, particularly when the diagnostic study being assessed
s bound to influence the clinician’s choice of therapy. It is
nclear what constituted medical therapy and how compliant
atients were. This particularly applies to those treated with
ABG in whom medical therapy should be optimized maxi-
ally post-operatively but may not always occur. Optimal
medical therapy” should also arguably include the implanta-
ion of cardiac resynchronization devices and implantable
ardioverter-defibrillators (ICDs), which occurred at a surpris-
ngly low rate in this cohort with severe ischemic LV dysfunc-
ion overall, with a possible bias against those with viable
yocardium and those who were revascularized (rates of ICD
n
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February 28, 2012:836–7 Myocardial Viability Imagingimplantation were: n  5, 25% of the medically treated with
onviable myocardium, vs. n  1, 4% of the medically treated
ith viable myocardium, vs. 0% in the revascularized group).
welve (30%) of the cardiac deaths were sudden, and presum-
bly arrhythmic. Patients who have undergone CABG or PCI,
ut do not sufficiently recover their LV function, remain at
igh risk for sudden cardiac death and thus, meet criteria for an
CD with or without cardiac resynchronization therapy place-
ent, which affects mortality. There was also no confirmation
f “full revascularization” versus “incomplete revascularization”
n terms of actual perfusion at both the epicardial and myo-
ardial level. Moreover, there was no follow-up CMR imaging
eported in this study, which could have provided significant
nsight into pathophysiological mechanisms why revasculariza-
ion is or is not beneficial in these patients. Were there
erioperative ischemic events/infarctions or ischemia/
nfarction caused by subsequent graft occlusions that contrib-
ted to the worse outcome of the revascularized, nonviable
atients? Is prognosis directly related to the extent of functional
ecovery? A prior publication by Gerber et al. (7) included a
ubset of 22 patients from the current cohort who underwent
epeat DE-CMR 10  7 months following complete revas-
ularization, and global LV function improved from 25  8%
o 33  10% (B. Gerber, personal communication), but the
xtent of functional recovery and its relationship to outcome is
ot known for the other treatment groups.
The pathophysiology of hibernation involves reduced
yocardial blood flow, particularly to the subendocardium,
nd may be evident at rest but always manifests as reduced
oronary flow reserve (8). Structural changes also occur, most
rominently in dysfunctional regions but also in remote,
ormally contracting segments (8). These consist of reductions
n microvessel density and cross-sectional area, depletion of
yocyte contractile elements, and collagen replacement within
he extracellular matrix, which may be of varying severity and
eversibility and likely affect the success of revascularization (8).
ecause of its versatility, CMR has the potential to address
any aspects of the pathophysiological response of the chron-
cally ischemic, dysfunctional ventricle to revascularization.
ransmural extent of DE assesses only 1 aspect of this complex
rocess, that of scar/collagen replacement, and suffers from
educed diagnostic performance for predicting functional re-
overy when there is intermediate extents of transmurality
9,10). The ability of CMR to assess resting perfusion and
oronary flow reserve, myocardial energetics, and quantitative
egional wall motion using tissue tagging during rest and stress
rovocation (inotropic reserve) should be capitalized upon
ecause there may be better predictive value in assessing
ultiple aspects of viability in a tiered approach rather than 1
omponent. In addition, a multipronged approach may lead to
nsights regarding the mechanisms behind the dissociation
etween functional recovery and improved outcomes that is
ften seen, that is, improved outcome despite lack of functional
ecovery that may in part be attributable to preservation of the
nfarct border zone integrity that leads to reductions in ven-
ricular arrhythmogenesis (11).As evident by STICH, HEART, and the current study,
nrollment in these types of protocols is extremely difficult,
nd underenrollment will continue to be a significant
oncern for any future trials. Differences in baseline clinical
haracteristics will also be strong confounding factors in
onrandomized trials. To overcome some of these issues, in
ddition to clinical outcomes and mortality, it would be vital
or future study designs to incorporate comprehensive im-
ging both at baseline and in follow-up to better understand
nd characterize the pathophysiological state of the myo-
ardium before and after interventions with the goal of
eveloping tailored therapeutic plans based on each individ-
al’s specific myocardial phenotype, which may require the
ssessment of a combination of factors that define viability
perfusion status and perfusion reserve, metabolism, scar
xtent and peri-infarct anatomy, and/or contractile reserve)
n a tiered approach that remains to be defined.
Thus, rumors of its demise are greatly exaggerated:
yocardial viability testing is alive and well, but we need to
mprove how we use it.
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